Astrazeneca Plc (AZN)

$70.13

+1.58

(+2.3%)▲

Market is closed - opens 7 PM, 23 Apr 2024
star icon

AstraZeneca plc is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines.

Insights on Astrazeneca Plc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 10.87B → 12.02B (in $), with an average increase of 3.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 1.81B → 960.0M (in $), with an average decrease of 27.3% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 89.8% return, outperforming this stock by 97.0%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 287.5% return, outperforming this stock by 253.3%

Performance

  • $69.40
    $70.47
    $70.13
    downward going graph

    1.04%

    Downside

    Day's Volatility :1.52%

    Upside

    0.48%

    downward going graph
  • $58.65
    $73.29
    $70.13
    downward going graph

    16.37%

    Downside

    52 Weeks Volatility :19.98%

    Upside

    4.31%

    downward going graph

Returns

PeriodAstrazeneca PlcSector (Health Care)Index (NASDAQ Composite)
3 Months
5.06%
-0.4%
0.2%
6 Months
11.23%
9.6%
18.7%
1 Year
-7.49%
3.9%
28.0%
3 Years
34.19%
12.8%
10.2%

Highlights

Market Capitalization
212.5B
Book Value
$25.25
Dividend Share
2.9
Dividend Yield
2.11%
Earnings Per Share (EPS)
1.91
PE Ratio
35.89
PEG Ratio
0.89
Wall Street Target Price
81.81
Profit Margin
13.0%
Operating Margin TTM
16.92%
Return On Assets TTM
6.6%
Return On Equity TTM
15.64%
Revenue TTM
45.8B
Revenue Per Share TTM
2.45
Quarterly Revenue Growth YOY
7.3%
Gross Profit TTM
35.7B
EBITDA
15.0B
Diluted Eps TTM
1.91
Quarterly Earnings Growth YOY
0.06
EPS Estimate Current Year
4.56
EPS Estimate Next Year
5.13
EPS Estimate Current Quarter
0.79
EPS Estimate Next Quarter
1.01

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 37 Wall street analysts offering stock ratings for Astrazeneca Plc(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
31
31
30
Hold
6
6
9
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 16.65%

Current $70.13
Target $81.81

Company Financials

FY18Y/Y Change
Revenue
22.1B
↓ 1.67%
Net Income
2.2B
↓ 28.19%
Net Profit Margin
9.76%
↓ 3.6%
FY19Y/Y Change
Revenue
24.4B
↑ 10.38%
Net Income
1.3B
↓ 38.05%
Net Profit Margin
5.47%
↓ 4.29%
FY20Y/Y Change
Revenue
26.6B
↑ 9.16%
Net Income
3.2B
↑ 139.4%
Net Profit Margin
12.01%
↑ 6.54%
FY21Y/Y Change
Revenue
37.4B
↑ 40.58%
Net Income
112.0M
↓ 96.5%
Net Profit Margin
0.3%
↓ 11.71%
FY22Y/Y Change
Revenue
44.4B
↑ 18.53%
Net Income
3.3B
↑ 2835.71%
Net Profit Margin
7.41%
↑ 7.11%
FY23Y/Y Change
Revenue
45.8B
↑ 3.29%
Net Income
6.0B
↑ 81.11%
Net Profit Margin
13.0%
↑ 5.59%
Q3 FY22Q/Q Change
Revenue
11.0B
↑ 1.96%
Net Income
1.6B
↑ 355.56%
Net Profit Margin
14.93%
↑ 11.59%
Q4 FY22Q/Q Change
Revenue
11.2B
↑ 2.05%
Net Income
901.0M
↓ 45.06%
Net Profit Margin
8.04%
↓ 6.89%
Q1 FY23Q/Q Change
Revenue
10.9B
↓ 2.93%
Net Income
1.8B
↑ 100.11%
Net Profit Margin
16.57%
↑ 8.53%
Q2 FY23Q/Q Change
Revenue
11.4B
↑ 4.94%
Net Income
1.8B
↑ 0.83%
Net Profit Margin
15.93%
↓ 0.64%
Q3 FY23Q/Q Change
Revenue
11.5B
↑ 0.67%
Net Income
1.4B
↓ 24.42%
Net Profit Margin
11.96%
↓ 3.97%
Q4 FY23Q/Q Change
Revenue
12.0B
↑ 4.63%
Net Income
960.0M
↓ 30.13%
Net Profit Margin
7.98%
↓ 3.98%
FY18Y/Y Change
Total Assets
60.7B
↓ 4.27%
Total Liabilities
46.6B
↓ 0.22%
FY19Y/Y Change
Total Assets
61.4B
↑ 1.2%
Total Liabilities
46.8B
↑ 0.37%
FY20Y/Y Change
Total Assets
66.7B
↑ 8.72%
Total Liabilities
51.1B
↑ 9.21%
FY21Y/Y Change
Total Assets
105.4B
↑ 57.9%
Total Liabilities
66.1B
↑ 29.33%
FY22Y/Y Change
Total Assets
96.5B
↓ 8.43%
Total Liabilities
59.4B
↓ 10.07%
FY23Y/Y Change
Total Assets
101.1B
↑ 4.8%
Total Liabilities
62.0B
↑ 4.25%
Q3 FY22Q/Q Change
Total Assets
94.2B
↓ 2.48%
Total Liabilities
59.0B
↓ 2.63%
Q4 FY22Q/Q Change
Total Assets
96.5B
↑ 2.44%
Total Liabilities
59.4B
↑ 0.67%
Q1 FY23Q/Q Change
Total Assets
96.7B
↑ 0.21%
Total Liabilities
60.9B
↑ 2.44%
Q2 FY23Q/Q Change
Total Assets
96.5B
↓ 0.15%
Total Liabilities
59.1B
↓ 2.87%
Q3 FY23Q/Q Change
Total Assets
96.1B
↓ 0.47%
Total Liabilities
58.9B
↓ 0.44%
Q4 FY23Q/Q Change
Total Assets
101.1B
↑ 5.24%
Total Liabilities
62.0B
↑ 5.25%
FY18Y/Y Change
Operating Cash Flow
2.6B
↓ 26.83%
Investing Cash Flow
963.0M
↓ 141.37%
Financing Cash Flow
-2.0B
↓ 30.38%
FY19Y/Y Change
Operating Cash Flow
3.0B
↑ 13.41%
Investing Cash Flow
-657.0M
↓ 168.22%
Financing Cash Flow
-1.8B
↓ 13.65%
FY20Y/Y Change
Operating Cash Flow
4.8B
↑ 61.64%
Investing Cash Flow
-285.0M
↓ 56.62%
Financing Cash Flow
-2.2B
↑ 24.82%
FY21Y/Y Change
Operating Cash Flow
6.0B
↑ 24.26%
Investing Cash Flow
-11.1B
↑ 3780.0%
Financing Cash Flow
3.6B
↓ 265.64%
FY22Y/Y Change
Operating Cash Flow
9.8B
↑ 64.48%
Investing Cash Flow
-3.0B
↓ 73.23%
Financing Cash Flow
-6.8B
↓ 286.98%
FY23Y/Y Change
Operating Cash Flow
10.3B
↑ 5.48%
Investing Cash Flow
-4.1B
↑ 37.3%
Financing Cash Flow
-6.6B
↓ 3.75%
Q3 FY22Q/Q Change
Operating Cash Flow
2.9B
↑ 134.78%
Investing Cash Flow
-1.7B
↑ 117.88%
Financing Cash Flow
-1.4B
↑ 10.42%
Q4 FY22Q/Q Change
Operating Cash Flow
2.4B
↓ 18.16%
Investing Cash Flow
-249.0M
↓ 85.71%
Financing Cash Flow
-358.0M
↓ 74.97%
Q1 FY23Q/Q Change
Operating Cash Flow
3.1B
↑ 30.65%
Investing Cash Flow
-1.2B
↑ 400.4%
Financing Cash Flow
-2.0B
↑ 467.32%
Q2 FY23Q/Q Change
Operating Cash Flow
1.7B
↓ 45.16%
Investing Cash Flow
-520.0M
↓ 58.27%
Financing Cash Flow
-1.5B
↓ 25.21%
Q3 FY23Q/Q Change
Operating Cash Flow
3.1B
↑ 81.26%
Investing Cash Flow
-1.2B
↑ 134.81%
Financing Cash Flow
-2.7B
↑ 79.46%
Q4 FY23Q/Q Change
Operating Cash Flow
2.4B
↓ 23.57%
Investing Cash Flow
-1.1B
↓ 11.79%
Financing Cash Flow
-291.0M
↓ 89.33%

Technicals Summary

Sell

Neutral

Buy

Astrazeneca Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Astrazeneca Plc
Astrazeneca Plc
6.48%
11.23%
-7.49%
34.19%
81.26%
Eli Lilly And Company
Eli Lilly And Company
-5.41%
26.82%
90.77%
287.52%
522.46%
Johnson & Johnson
Johnson & Johnson
-3.93%
-1.5%
-8.9%
-9.91%
6.59%
Merck & Co. Inc.
Merck & Co. Inc.
1.3%
22.83%
9.49%
62.99%
70.16%
Abbvie Inc
Abbvie Inc
-5.96%
16.0%
2.32%
50.74%
113.44%
Pfizer Inc.
Pfizer Inc.
-4.27%
-14.85%
-34.2%
-32.07%
-33.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Astrazeneca Plc
Astrazeneca Plc
35.89
35.89
0.89
4.56
0.16
0.07
0.02
25.25
Eli Lilly And Company
Eli Lilly And Company
125.01
125.01
1.43
12.5
0.48
0.12
0.01
11.98
Johnson & Johnson
Johnson & Johnson
19.91
19.91
0.89
10.65
0.18
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
898.43
898.43
0.1
8.56
0.01
0.03
0.02
14.85
Abbvie Inc
Abbvie Inc
61.41
61.41
0.45
11.11
0.35
0.08
0.04
5.87
Pfizer Inc.
Pfizer Inc.
70.27
70.27
0.26
2.21
0.02
0.02
0.06
15.77
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Astrazeneca Plc
Astrazeneca Plc
Buy
$212.5B
81.26%
35.89
13.0%
Eli Lilly And Company
Eli Lilly And Company
Buy
$690.6B
522.46%
125.01
15.36%
Johnson & Johnson
Johnson & Johnson
Hold
$356.4B
6.59%
19.91
47.37%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$318.6B
70.16%
898.43
0.61%
Abbvie Inc
Abbvie Inc
Buy
$294.7B
113.44%
61.41
8.95%
Pfizer Inc.
Pfizer Inc.
Buy
$147.2B
-33.38%
70.27
3.62%

Institutional Holdings

  • T. Rowe Price Associates, Inc.

    1.69%

  • Wellington Management Company LLP

    1.59%

  • PRIMECAP Management Company

    1.39%

  • Capital Research & Mgmt Co - Division 3

    1.12%

  • Goldman Sachs Group Inc

    0.74%

  • FMR Inc

    0.69%

Corporate Announcements

  • Astrazeneca Plc Dividends March,2024

    In the quarter ending March,2024. Astrazeneca Plc has declared dividend of $0.99

    Read More

Company Information

AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca Plc has a market cap of $212.54 Billion. It has a P.E ratio of 35.69. The shares of Astrazeneca Plc are trading at $70.13. .

Organization
Astrazeneca Plc
Employees
89900
CEO
Mr. Pascal Soriot D.V.M., M.B.A.
Industry
Health Technology

Discover More

FAQs